High Frame Rate Ultrasound in Heart Disease Assessment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will compare standard ultrasound images to high frame rate ultrasound images in patients with heart disease or with a low risk of heart disease to see if a higher frame rate of ultrasound adds to the information obtained from standard ultrasound.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease

NCT00001632

Healthy Hypertrophic Cardiomyopathy Left Ventricular Hypertrophy

COMPLETED

Ultra-high-resolution CT vs. Conventional Angiography for Detecting Coronary Heart Disease

NCT04272060

Coronary Artery Disease

COMPLETED NA

Quantification of Myocardial Fibrosis in Aortis Stenosis

NCT06571175

Aortic Valve Stenosis Myocardial Fibrosis

ENROLLING_BY_INVITATION

Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function

NCT00661323

Ischemia Myocardial Infarction Ischemic Heart Disease

COMPLETED

Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI.

NCT02014701

STEMI

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Following informed consent, patients recruited for the study will have an IV cannula inserted and will undergo imaging using 2 ultrasound systems. Standard clinical system (Philips IE33) will be used for 2D and CE imaging, followed by imaging using the Verasonics VantageTM research system (Verasonics Inc., Redmond, WA), using both conventional 2D and HFR modes.

Baseline unenhanced 2D and Doppler images would initially be acquired using Philips IE33 system and Verasonics VatangeTM unenhanced conventional 2D and HFR mode .

Ultrasound contrast agent (Sonovue) will be then injected via the intravenous (iv) cannula and 3 sets rest contrast images will be acquired - using the Phillips IE33, Verasonics and Verasonics VantageTM platform (conventional CE and HFR CE). Both systems will be optimised separately on each patient before and during infusion of contrast agent. When the optimal imaging and destruction parameters are set, there are not modified along the acquisition.

This is followed by dipyridamole infusion and the scans being repeated during stress - 3 sets contrast images will be acquired - using the Philips IE33 and Verasonics VantageTM platform (conventional CE and HFR CE).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard echocardiography

Patients will undergo standard echocardiography, with and without contrast

Intervention Type DIAGNOSTIC_TEST

High frame rate echocardiography

Following standard echocardiography, the test is repeated using high frame rate ultrasound

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to give informed consent
* age ≥18years and
* confirmed inducible wall motion / perfusion abnormality on previous stress echocardiogram
* known coronary artery disease - defined by presence of flow-limiting coronary stenosis(\>70% diameter stenosis) on coronary angiography.

OR

• patient who has been assessed as at low risk of having coronary heart disease

Exclusion Criteria

* Inability to undertake pharmacological stress, ie previously known intolerance to dipyridamole;
* Moderate or Severe aortic or mitral regurgitation or severe mitral stenosis;
* Significant pulmonary disease like severe COPD or pulmonary fibrosis;
* Atrial fibrillation;
* Inability to provide informed consent;
* Pregnancy and lactation;
* Known allergy to Sonovue
* Patients with second and third degree heart block, unless they have a pacemaker fitted
* Systolic BP \< 90
* Known Myasthenia Gravis
* Bronchial asthma

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No